TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02335060
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (about a quarter spoon of alcohol with no THC) given intravenously.
Study: NCT02335060
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo sugar pill given orally with no N-acetylcysteine.
Study: NCT03757754
Drug: HPPH 2.5 mg/m2
Approvals — FDA: no, EMA: no, PMDA: no
Description: HPPH was administered as a single, 2.5 mg/m2, slow intravenous infusion over 1 hour , and a fixed light dose of 150 J/cm delivered 48 hours after infusion of HPPH.
Study: NCT03757754
Drug: HPPH 3 mg/m2
Approvals — FDA: no, EMA: no, PMDA: no
Description: HPPH was administered as a single, 3 mg/m2, slow intravenous infusion over 1 hour, and a fixed light dose of 150 J/cm delivered 48 hours after infusion of HPPH.
Study: NCT03757754
Drug: HPPH 3.5 mg/m2
Approvals — FDA: no, EMA: no, PMDA: no
Description: HPPH was administered as a single, 3.5 mg/m2, slow intravenous infusion over 1 hour, and a fixed light dose of 150 J/cm delivered 48 hours after infusion of HPPH.
Study: NCT03757754
Drug: HPPH 4 mg/m2
Approvals — FDA: no, EMA: no, PMDA: no
Description: HPPH was administered as a single, 4 mg/m2, slow intravenous infusion over 1 hour, and a fixed light dose of 150 J/cm delivered 48 hours after infusion of HPPH.
Study: NCT03757754
Drug: HPPH 5 mg/m2
Approvals — FDA: no, EMA: no, PMDA: no
Description: HPPH was administered as a single, 5 mg/m2, slow intravenous infusion over 1 hour, and a fixed light dose of 150 J/cm delivered 48 hours after infusion of HPPH.
Study: NCT03757754
Drug: HPPH 6 mg/m2
Approvals — FDA: no, EMA: no, PMDA: no
Description: HPPH was administered as a single, 6 mg/m2, slow intravenous infusion over 1 hour, and a fixed light dose of 150 J/cm delivered 48 hours after infusion of HPPH.
Study: NCT01060267
Drug: Erythromycin
Normalized name: Erythromycin
DrugBank: Erythromycin (DB00199)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The patients in erythromycin group received intravenous bolus infusion of 125 mg of erythromycin lactobionate in 50 ml of normal saline
Study: NCT01060267
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: patients in placebo group 50ml of normal saline over 10 minutes, 1/2 hour before endoscopy.
Study: NCT04402541
Drug: CB-5339
Normalized name: BroveX CB
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25mg and 75mg capsules
Study: NCT00558272
Drug: AZD0530
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily oral dose
Study: NCT00558272
Drug: Zoledronic Acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT02472236
Drug: PEX168
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200µg,injected subcutaneously,once a week.
Study: NCT01836393
Drug: Plavina cream
Normalized name: NIACINAMIDE 2 g in 100 g / ADENOSINE 0.04 g in 100 g TOPICAL CREAM [TAEYANGSOO Plavital RxCream]
Approvals — FDA: no, EMA: no, PMDA: no
Description: The essential plai cream has anti-inflammatory and antimicrobial effects (Wasuwat1989, Giwanon 2000, Pithayanukul 2007, and Tripathi 2008). Active chemicals of plai cream are composed of sabinene, alpha and gamma tepinenes, terpinen 4-ol and (E)-1-(3,4-dimethoxyphenyl butadiene (DMPBD). The DMPBD has a property of anti-inflammatory activity(Ozaki 1991, Jeenapongsa 2003). Plavina® 40 mg in 100 gm (contains DMPBD of ...%). This product was supplied in lacquered aluminum collapsible tube containing 100 gram cream packing.
Study: NCT01342562
Drug: spinal anesthesia
Normalized name: Bos taurus spinal cord preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.4% bupivacaine(normal saline 0.3ml with dexmedetomidine 3 mcg)
Study: NCT01342562
Drug: spinal anesthesia
Normalized name: Bos taurus spinal cord preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.4% bupivacaine(normal saline 0.3 ml with 0.5% bupivacaine 1.2 ml)
Study: NCT01147497
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pill that is identical to the study drug in appearance, taste and smell, taken buccally 2 hours prior to IUD insertion visit
Study: NCT00245271
Drug: OMS103HP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maximum of 13 bags of OMS103HP irrigation solution over a maximum of 2 hours
Study: NCT00245271
Drug: Vehicle
Normalized name: Drug vehicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maximum of 13 bags of BSS irrigation over a maximum of 2 hours.
Study: NCT02543931
Drug: Meriva
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meriva is an enhanced-bioavailability, curcuminoid-enriched turmeric dietary supplement that is sold over the counter in the United States and other countries.
Study: NCT02543931
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules containing inert ingredients
Study: NCT00648531
Drug: Colazal® Capsules 750 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3x750mg, single dose fasting
Study: NCT02014584
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dutasteride matching placebo will be supplied as capsules to be administered orally.
Study: NCT04122443
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen 650mg
Study: NCT00006455
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00006455
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00006455
Drug: leucovorin calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00006455
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00006455
Drug: therapeutic hydrocortisone
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02161419
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive placebo treatment as a 3 days on / 4 days schedule off with two tablets twice daily during 6 cycles (21 days each) of chemotherapy with Carboplatin/etoposide or Cisplatin/etoposide and continue thereafter as monotherapy until tumor progression, unacceptable toxicity, death, consent withdrawal, or withdrawal from the study
Study: NCT00552604
Drug: standardized cannabis extract
Normalized name: Cannabis sativa whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cannabis extract (delta-9-THC 2.5mg, CBD 1.25 mg per capsule), flexible dosing between 5 mg and 25 mg THC/d, administered twice daily
Study: NCT00552604
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo capsules, twice daily
Study: NCT03693781
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corresponding tablets for 30 weeks
Study: NCT00527332
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 100-200 microgram IV (intravenously) at start of anesthesia. 50-100 microgram IV on demand during surgery.
Study: NCT00527332
Drug: Rocuronbromid
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.6 mg/kg body weight IV (intravenously) at induction of anesthesia. If additional muscle relaxation is needed during surgery 5-10 mg is injected IV. The drug is given only at induction of anesthesia and during surgery
Study: NCT00302757
Drug: Radioimmunotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02160145
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo tablets will be self-administered orally as split-dose regimens, once upon awakening and another approximately 8 to 9 hours later
Study: NCT02012049
Drug: Risperdal OD Tab. 2mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 tablet Risperdal OD 2 mg administered orally.
Study: NCT02012049
Drug: Risperdal Quicklet Tab. 2mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 tablet Risperdal Quicklet Tab. 2mg administered orally.
Study: NCT03667690
Drug: intravenous placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline
Study: NCT03667690
Drug: oral placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Microcrystalline cellulose
Study: NCT01307462
Drug: azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given PO
Study: NCT01340183
Drug: AZD5099
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV Dose
Study: NCT01340183
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV Dose
Study: NCT02915744
Drug: NKTR-102
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00168454
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (normal saline) injected into detrusor on Day 1
Study: NCT04584242
Drug: suganon tab 5mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: frosting and formulation : pink circular film coating tablets path of administration : once a day, one tabs, oral Amount of raw material medication (1 pill) : Evogliptin tartrate 6.869mg(5mg as evogliptin) storage method : Confidential containers, stored at room temperature (1-30°C) manufacturing source : DONG-A ST
Study: NCT00355264
Drug: Phenoptin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5mg/kg/day orally, dose may be adjusted to between 5-20 mg/kg/day by investigator at week 6 to control blood Phe levels
Study: NCT01480739
Drug: 100 mg (50 mg x 2) AZD5069
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice daily for 7 days
Study: NCT01480739
Drug: 100 mg Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice daily for 7 days
Study: NCT02807870
Drug: Placebo pill
Normalized name: placebo Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo pill during 8 weeks.
Study: NCT00959127
Drug: ARRY-438162 (MEK162), MEK inhibitor; oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Part 1: multiple dose, escalating; Part 2: multiple dose, single schedule; Part 3: multiple dose, single schedule.
Study: NCT01103063
Drug: Azithromycin plus chloroquine
Normalized name: Chloroquine
DrugBank: Chloroquine (DB00608)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: combination tablet of 250mg azithromycin/155 chloroquine, Once daily PO for three days per treatment. There are total 3 treatments at 4-8 weeks intervals. The first treatment course will be administered during the second trimester (14-26 weeks of gestation as confirmed by ultrasound). The last treatment course should be given to subjects prior to or during 36 weeks of gestation.
Study: NCT00357617
Drug: celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00969293
Drug: FOV2302 (Ecallantide)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single intravitreal injection into the relevant eye.~Five dose levels will be studied from 5 to 90µg and a maximum of 6 subjects will be included at each dose level.~Duration of Treatment: Single injection with 3 months follow-up.
Study: NCT04413929
Drug: Ergoferon
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration
Study: NCT01254799
Drug: Doxycycline
Normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 100 mg Doxycycline capsules twice daily for 5 days
Study: NCT01254799
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules twice daily for 5 days
Study: NCT00004031
Drug: CHOP regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00004031
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00004031
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03078062
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of a single-dose of Normal saline during spinal anesthesia
Study: NCT01413958
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to phenylephrine hydrochloride 30-mg extended release tablets, one tablet every 12 hours for 7 days
Study: NCT03124225
Drug: DMARD
Normalized name: Disease-modifying antirheumatic drug (DMARD)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03476044
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 patients will receive starch capsules orally with sips of water 2 hours before induction of anesthesia
Study: NCT00291720
Drug: Spironolactone
Normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All patients receive a 4 week open labeled run in phase of 25mg spironolactone daily after which they are randomized to continue or receive matched placebo for 8 months.
Study: NCT00291720
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: matching placebo
Study: NCT04482296
Drug: SSRI with Zinc Sulfate
Normalized name: Zinc Sulfate
DrugBank: Zinc acetate (DB14487)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Zinc sulfate (30 mg) once daily for 8 weeks SSRI
Study: NCT00304785
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02420496
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02065674
Drug: Abroma Augusta Q (mother tincture)
Normalized name: Chew Q
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 drops in 1 cup of water three times a day for 3 months
Study: NCT01916304
Drug: Levothyroxine sodium new formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levothyroxine tablets
Study: NCT04652128
Drug: Zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Subject will receive a single infusion of zoledronic acid 5mg/100mL intravenously.
Study: NCT04652128
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subject will receive a single infusion of physiological saline 100mL intravenously.
Study: NCT03555526
Drug: Clarithromycin ER
Normalized name: Clarithromycin ER
Approvals — FDA: no, EMA: no, PMDA: no
Description: clarithromycin 500mg, bid, for 7 days (day 8-14)
Study: NCT03555526
Drug: tetracycline
Normalized name: Tetracycline
DrugBank: Tetracycline (DB00759)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: tetracycline 500mg, qid, for 10 days
Study: NCT01611324
Drug: Mepivacaine chlorhydrate 2% with epinephrine in NS 0.9%
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mL mepivacaine chlorhydrate 20 mg/mL with epinephrine 5 mcg/mL diluted with 16 mL sodium chloride 0.9%
Study: NCT01778166
Drug: Immuno-enhanced
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediately drip 37°C saline 20 ml/h and exchange to drip 37°C enteral nutrition fluid concerning omega-3-unsaturated fatty acids 20 ml/h at postoperative 6 h via jejunostomy tube or nasogastric tube
Study: NCT01778166
Drug: Standard early enteral nutrition
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediately drip 37°C saline 20 ml/h and exchange to drip 37°C standard enteral nutrition fluid 20 ml/h at postoperative 6 h via jejunostomy tube or nasogastric tube
Study: NCT00399334
Drug: antipsychotic medications
Approvals — FDA: no, EMA: no, PMDA: no
Description: as prescribed
Study: NCT02753894
Drug: ASP1585
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral
Study: NCT01027793
Drug: Tretinoin cream 0.005%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 1 will receive tretinoin cream 0.05%(Vitanol A, Stiefel) that should be applied daily in areas affected by stretch marks, in both sides, for a period of 16 weeks.
Study: NCT04475328
Drug: AngongNiuhuang pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: This group will receive AngongNiuhuang pill 1pill qd/day for 5-day.
Study: NCT04475328
Drug: Placebo of AngongNiuhuang pill
Normalized name: placebo Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: This group will receive placebo of AngongNiuhuang pill 1pill qd/day for 5-day.
Study: NCT00745108
Drug: CE/MPA
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral, 0.625 mg tablet conjugated equine estrogen and 2.5 mg medroxyprogesterone acetate tablet placed together in a single capsule, once daily, for 2 years
Study: NCT00031460
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral banana flavored placebo suspension: to be given at least 6 to 8 hours apart for 6 months. Dosage adjustments will be made monthly to compensate for increases in body surface area.
Study: NCT02198794
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matching to SD-809 will be administered per schedule specified in the arm.
Study: NCT00192452
Drug: MEDI-507
Normalized name: Medi-Lyte
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03362515
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT00690638
Drug: PHX1149T
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg
Study: NCT00690638
Drug: PHX1149T
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg
Study: NCT00690638
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT02584309
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01114516
Drug: Indomethacin and antibiotics (cefazolin or clindamycin)
Normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: q8hr dosing of po indomethacin 50mg X 24 hrs and q8 hr 1 g IV cefazolin or 600 mg IV clindamycin
Study: NCT01035879
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: tablets and capsule once daily
Study: NCT00810121
Drug: ketoprofen 100 mg
Normalized name: ketoprofen 100 MG
DrugBank: Ketoprofen (DB01009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 100 mg b.i.d. for 5 days
Study: NCT00810121
Drug: ketoprofen
Normalized name: Ketoprofen
DrugBank: Ketoprofen (DB01009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 150 mg b.i.d. for 5 days
Study: NCT00373243
Drug: GW406381
Approvals — FDA: no, EMA: no, PMDA: no
Description: GW406381 will be available as 10 mg hard gelatin capsules. Subjects will receive two capsules of 10 mg to make 20 mg dose.
Study: NCT00787410
Drug: ZD1839
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250mg tablet, once daily, orally administered
Study: NCT00385970
Drug: Krestin (PSK)
Approvals — FDA: no, EMA: no, PMDA: no
Description: From within 9 weeks after surgery to 12 months after surgery, 3 g/day, PO every day
Study: NCT01122199
Drug: RAD001 + AMG479
Approvals — FDA: no, EMA: no, PMDA: no
Description: Escalating doses of RAD001 + AMG479. Starting cohort will be 5 mg RAD001 once daily, continuous + AMG479 12 mg/kg on Day 1 and 15 of each 28 day cycle.
Study: NCT02526381
Drug: Danlou Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Five tablets of Danlou Tablets (1.5g) will be given three times a day in addition to regular western medications for the 8 weeks
Study: NCT02526381
Drug: Tongmai Yangxin Pills
Approvals — FDA: no, EMA: no, PMDA: no
Description: Forty pills of Tongmai Yangxin Pills (4g) will be given two times a day in addition to regular western medications for the 8 weeks
Study: NCT01336738
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets (n=6), 0 mg, once daily for 84 days
Study: NCT02753647
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02753647
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01101841
Drug: Placebo capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eligible subjects will be randomized to receive either Brisdelle (paroxetine mesylate) Capsules 7.5 mg or placebo capsules in a 1:1 ratio.
Study: NCT01034917
Drug: Continue with the same antiretroviral regimen
Normalized name: Anacin Aspirin Regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continue with the same antiretroviral regimen
Study: NCT03003520
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A component of the CHOP therapy administered by IV. CHOP therapy was administered following rituximab.
Study: NCT03003520
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: A component of the CHOP therapy administered by IV. CHOP therapy was administered following rituximab.
Study: NCT03853707
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given PO
Study: NCT01032629
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: One placebo capsule taken orally (by mouth) once daily
Study: NCT03111992
Drug: PDR001
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-PD1 antibody
Study: NCT03111992
Drug: CJM112
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-IL-17A antibody
Study: NCT03111992
Drug: LCL161
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral small molecule SMAC-mimetic
Study: NCT03371355
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (Matched with ISIS 703802)
Study: NCT02722694
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: All Subjects received backup Methotrexate treatment.
Study: NCT01920802
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: BID up to 4 weeks
Study: NCT02472756
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: The choice of the chemotherapy regimen will be established on a per center basis, according to the standard in use in the country and in the center. Protocol does not specify any particular chemotherapy regimen.
Study: NCT03748940
Drug: LY3074828
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC
Study: NCT03748940
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC
Study: NCT03748940
Drug: LY900021
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC
Study: NCT04699994
Drug: FLOT therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preoperative FLOT therapy
Study: NCT01973855
Drug: Western Medicine
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical cooling,Hydrocortisone
Study: NCT01973855
Drug: TCM and Western Medicine
Normalized name: western larch pollen extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Third Infectious diseases soup recipe